Clinical Trial Update: HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications [Phase 4]

View source ↗

Summary

Phase 4 trial comparing hydrocortisone to pasireotide in reducing pancreatic surgery complications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Fistula
• Pancreatic Neoplasms

Drugs mentioned

• HYDROCORTISONE (HYDROCORTISONE)
• Pasireotide (pasireotide)

Snippet

Sponsor: Helsinki University Central Hospital | Conditions: Pancreatic Fistula, Pancreatic Neoplasms | Phase 4 | Status: ACTIVE_NOT_RECRUITING